Publications

Selected peer-reviewed manuscripts

Bragazzi Cunha J, Leix K, Sherman EJ, Mirabelli C, Frum T, Zhang CJ, Kennedy AA, Lauring AS, Tai AW, Sexton JZ, Spence JR, Wobus CE, Emmer BT: Type I interferon signaling induces a delayed antiproliferative response in respiratory epithelial cells during SARS-CoV-2 infection. J Virol 2023; 97:e0127623. Link to PubMed

Williams JM, Chen Y-J, Cho WJ, Tai AW, Tsai B: Reticulons promote formation of ER-derived double-membrane vesicles that facilitate SARS-CoV-2 replication. J Cell Biol 2023;222:e202203060.  Link to PubMed

Bagchi P, Speckhart K, Kennedy A, Tai AW, Tsai B: A specific EMC subunit supports Dengue virus infection by promoting virus membrane fusion essential for cytosolic genome delivery. PLoS Pathog 2022;18:e1010717. Link to PubMed

Sherman EJ, Mirabelli C, Tang VT, Khan TG, Leix K, Kennedy AA, Graham SE, Willer CJ, Tai AW, Sexton JZ, Wobus CE, Emmer BT. Identification of cell type specific ACE2 modifiers by CRISPR screening. PLoS Pathog 2022;18:e1010377.  Link to PubMed

Zafferani M, Haddad C, Luo L, Davila-Calderon J, Yuan-Chiu L, Shema Mugisha C, Monaghan AG, Kennedy AA, Yesselman JD, Gifford RR, Tai AW, Kutluay SB, Li ML, Brewer G, Tolbert BS, Hargrove AE. Amilorides inhibit SARS-CoV-2 replication in vitro by targeting RNA structures. Sci Adv 2021;7:eabl6096. Link to PubMed 

Jangra S, Landers JJ, Rathnasinghe R, O’Konek JJ, Janczak KW, Cascalho M, Kennedy AA, Tai AW, Baker JR Jr, Schotsaert M, Wong PT. A combination adjuvant for the induction of potent antiviral immune responses for a recombinant SARS-CoV-2 protein vaccine. Front Immunol 2021;12:729189. Link to PubMed 

Schuler CF, Gherasim C, O’Shea K, Manthei DM, Chen J, Zettel C, Troost JP, Kennedy AA, Tai AW, Giacherio DA, Valdez R, Baldwin JL, Baker JR, Jr. Mild SARS-CoV-2 illness is not associated with reinfections and provides persistent spike, nucleocapsid, and virus neutralizing antibodies. Microbiology Spectrum 2021;9:e0008721. Link to PubMed 

Zupancic JM, Desai AA, Schardt JS, Pornnoppadol G, Makowski EK, Smith MD, Kennedy AA, Barbosa MGM, Cascalho C, Lanigan TM, Tai AW, Tessier PM. Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis. Cell Chem Biol 2021;28:1379-1388.e7. Link to PubMed 

Barbosa MGM, Liu H, Huynh D, Shelley G, Keller ET, Emmer BT, Sherman E, Ginsburg D, Kennedy AA, Tai AW, Wobus C, Mirabelli C, Lanigan TM, Samaniego M, Meng W, Rosenfeld AM, Luning Prak ET, Platt JL, Cascalho M. IgV somatic mutation of human anti-SARS-CoV-2 monoclonal antibodies governs neutralization and breadth of reactivity. JCI Insight 2021;6:147386  Link to PubMed

Wang HL* and Tai AW*. ­Nir2 is an effector of VAPs necessary for efficient HCV replication and PI(4)P enrichment at the viral replication organelle. J Virol 2019;93:e00742-19. *Co-corresponding authors. Link to PubMed

Lin DL, Inoue T, Chen YJ, Chang A, Tsai B*, and Tai AW*. The ER Membrane Protein Complex promotes biogenesis of dengue and Zika virus non-structural multi-pass transmembrane proteins to support infection. Cell Rep 2019;27:1666-74. *Co-corresponding authors. Link to PubMed

Flint M, Chatterjee P, Lin DL, McMullan LK, Shrivastava-Ranjan P, Bergeron E, Lo MK, Welch S, Nichol ST, Tai AW, and Spiropoulou CF. A genome-wide CRISPR screen identifies N-acetylglucosamine-1-phosphate transferase as a potential antiviral target for Ebola virus. Nat Commun 2019;10:285. Link to PubMed

Perry JW and Tai AW. Random insertional mutagenesis of a serotype 2 dengue virus clone. Bio-protocol 2018;8:e2975. Link to PubMed

Perry JW, Chen Y, Speliotes E, and Tai AW. Functional analysis of the dengue virus genome using an insertional mutagenesis screen. J Virol 2018;14:e02085-17. Link to PubMed

Lin DL, Cherepanova NA, Bozzacco L, MacDonald MR, Gilmore R and Tai AW. Dengue virus hijacks a noncanonical oxidoreductase function of a cellular oligosaccharyltransferase complex. mBio 2017;8:e00939-17. Link to PubMed

Wang H and Tai AW. Continuous de novo generation of spatially segregated hepatitis C virus replication organelles revealed by pulse-chase imaging. J Hepatol 2017;66:55-66. Link to PubMed

Cui J, Chen W, Sun J, Guo H, Madley R, Xiong Y, Pan X, Wang H, Tai AW, Weiss MA, Arvan P and Liu M. Competitive inhibition of the endoplasmic reticulum signal peptidase by non-cleavable mutant preprotein cargos. J Biol Chem 2015;290:28131-40. Link to PubMed

Chatterji U, Bobardt M, Tai A, Wood M, and Gallay PA. Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane vesicle viral factories. Antimicrob Agents Chemother 2015;59:2496-507. Link to PubMed

Wang H, Perry JW, Lauring AS, Neddermann P, De Francesco R, and Tai AW. Oxysterol-binding protein is a phosphatidylinositol 4-kinase effector required for HCV replication integrity and cholesterol trafficking. Gastroenterology 2014;146:1373-85. Link to PubMed

Salloum S*, Wang H*, Ferguson C, Parton RG, and Tai AW. Rab18 binds to hepatitis C virus NS5A and promotes interaction between sites of viral replication and lipid droplets. PLoS Pathog 2013;9:e1003513 *Equal contribution Link to PubMed 

Raveh A, Delekta PC, Dobry CJ, Peng W, Schultz PJ, Blakeley PK, Tai AW, Matainaho T, Irani DN, Sherman DH, and Miller DJ. Discovery of potent broad spectrum antivirals derived from marine actinobacteria. PLoS ONE 2013;8:e82318. Link to PubMed

Huang Y, Tai AW, Tong S, and Lok AS. HBV core promoter mutations promote cellular proliferation through E2F1-mediated upregulation of S-phase kinase associated protein 2 transcription. J Hepatol 2013;58:1068-73. Link to PubMed

Zhao H, Lin W, Kumthip K, Cheng D, Fusco DN, Hoffmann O, Jilg N, Tai AW, Goto K, Hide W, Jang JY, Peng LF, and Chung RT. A functional genomic screen reveals novel host genes that mediate interferon- alpha’s effects against hepatitis C virus. J Hepatol 2012;56:326-333. Link to PubMed

Tai AW* and Salloum S. The role of the phosphatidylinositol 4-kinase PI4KA in hepatitis C virus-induced host membrane rearrangement. PLoS ONE 2011;6:e26300. *Corresponding author. Link to PubMed

Tai AW*, Bojjireddy N, and Balla T. A homogenous and nonisotopic assay for phosphatidylinositol 4-kinases. Anal Biochem 2011;417:97-102. *Corresponding author. Link to PubMed

Huang Y, Tong S, Tai AW, Hussain M, and Lok AS. Hepatitis B virus core promoter mutations contribute to hepatocarcinogenesis via deregulation of SKP2 and its target p21. Gastroenterology 2011;141:1412-21. Link to PubMed

Szentpetry Z, Szakacs G, Bojjireddy N, Tai AW, and Balla T. Genetic and functional studies of phosphatidylinositol 4-kinase type IIIa. Biochim Biophys Acta 2011;1811:476-83. Link to PubMed

Tai AW, Benita Y, Peng LF, Kim, SS, Xavier RJ, and Chung RT. A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host & Microbe 2009;5:298-307 Link to PubMed

Kim KA, Lin W, Tai AW et al. Hepatic SOCS3 expression is strongly associated with nonresponse to therapy and race in HCV and HCV/HIV infection. J Hepatol;50:705-711. Link to PubMed

Lin W, Weinberg EM, Tai AW, Peng LF, Brockman MA, Kim KA, Kim SS, Borges CB, Shao RX, and Chung RT. HIV increases HCV replication in a TGF-beta1 dependent manner. Gastroenterology 2008;134:803-811. Link to PubMed

Tai AW, Chuang JZ, and Sung CH. Cytoplasmic dynein regulation by subunit heterogeneity and its role in apical transport. J Cell Biol 2001; 153:1499-1509. 

Tai AW*, Chuang JZ*, Bode C, Wolfrum U, and Sung CH. Rhodopsin's carboxy-terminal cytoplasmic tail acts as a membrane receptor for cytoplasmic dynein by binding to the dynein light chain Tctex-1. Cell 1999; 97:877-887. *Equal contribution

Tai AW, Chuang JZ, and Sung CH. Localization of Tctex-1, a cytoplasmic dynein light chain, to the Golgi apparatus and evidence for dynein complex heterogeneity J Biol Chem 1998; 273:19639-19649.

Reviews

Wang H and Tai AW. Mechanisms of cellular membrane reorganization to support hepatitis C virus replication. Viruses 2016;8:E142. Link to PubMed. 

Salloum S and Tai AW. Treating hepatitis C infection by targeting the host. Transl Res 2012;159:421-429.

Tai AW and Chung RT. Treatment failure in hepatitis C: mechanisms of non-response. J Hepatol 2009;50:412-420. Link to PubMed

Sung CH and Tai AW. Rhodopsin trafficking and its role in retinal dystrophies. Int Rev Cytology 2000; 195:215-267.

Book chapters

Tai AW and Vargas HE. (2022). Hepatitis C virus infection. In: Wang T and Camilleri M (Eds.), Yamada’s Textbook of Gastroenterology, 7th edition. Hoboken, NJ: Wiley. (in press)

Tai AW (2022). Viral hepatitis. In: Engleberg C, DiRita V, and Imperiale M (Eds.), Schaechter’s Mechanisms of Microbial Disease, 6th edition. Philadelphia, PA: Wolters Kluwer

Tai AW and Vidugiriene J. (2016). Measuring activity of phosphoinositide lipid kinases using a bioluminescent ADP-detecting assay. In: Zegzouti H and Goueli SA (Eds.), Kinase Screening and Profiling. New York, NY: Springer New York.

Tai AW and Chung RT. (2015). Hepatitis C virus infection. In: Podolsky DK (Ed.), Textbook of Gastroenterology, 6th edition. Hoboken, NJ: Wiley Blackwell.

Tai AW and Dienstag JL. (2009). Viral Hepatitis. In: Richman DD, Whitley RJ, and Hayden FG (Eds.), Clinical Virology, 3rd edition. (pp. 59-80) Washington DC: ASM Press.

Other media

Tai AW and Chung RT. (2009-17). Investigational therapies for hepatitis C virus infection. In: Basow DS (Ed), UpToDate. Waltham, MA: UpToDate. Web site; review article

Tai AW and Chung RT. (2009-14). Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1. In: Basow DS (Ed), UpToDate. Waltham, MA: UpToDate. Web site; review article